Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
76 hedge funds and large institutions have $218M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 9 closing their positions.
3% more capital invested
Capital invested by funds: $211M → $218M (+$6.34M)
0% more funds holding
Funds holding: 76 → 76 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$4.92M |
| 2 |
Millennium Management
New York
|
+$4.61M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.99M |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$1.87M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$4.92M |
| 2 |
HCM
Hawkeye Capital Management
Miami Beach,
Florida
|
-$2.95M |
| 3 |
Capstone Investment Advisors
New York
|
-$1.17M |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$1.09M |
| 5 |
RA
Ramius Advisors
New York
|
-$984K |
BIOT Hedge Fund Activity: Q1 2022 in Review
76 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2022, worth a combined $218M — up 3% from $211M a quarter earlier.
Fund positioning in BIOT was balanced in Q1 2022: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 15 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $4.92M. The largest seller was Blackstone Inc, exiting entirely with an estimated $4.92M sold.
- 76 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $218M of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2022, up 3% quarter-over-quarter.
- 9 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2022 and 9 closed out, a net change of 0 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q1 2022 was Mangrove Partners, an estimated $4.92M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q1 2022 was Blackstone Inc, an estimated $4.92M sold.
Based on aggregated 13F filings for Q1 2022.